| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
76,730,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
3 |
55,003 |
78,603 |
152,408 |
| Total Sell Value |
$91 |
$2,214,088 |
$3,185,947 |
$6,251,816 |
| Total People Sold |
1 |
2 |
4 |
7 |
| Total Sell Transactions |
1 |
4 |
6 |
13 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gannon Steven |
|
– • – |
2025-06-05 |
4 |
S |
$30.48 |
$91 |
D/D |
(3) |
7,141 |
|
- |
|
| Gannon Steven |
|
– • – |
2025-05-14 |
4 |
OE |
$12.57 |
$64,660 |
D/D |
5,144 |
7,144 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-27 |
4 |
AS |
$40.46 |
$660,806 |
D/D |
(16,315) |
31,302 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-27 |
4 |
OE |
$17.76 |
$289,754 |
D/D |
16,315 |
32,451 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-24 |
4 |
AS |
$40.20 |
$903,214 |
D/D |
(22,468) |
31,302 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-24 |
4 |
OE |
$17.76 |
$399,032 |
D/D |
22,468 |
53,770 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-23 |
4 |
AS |
$40.08 |
$649,977 |
D/D |
(16,217) |
31,302 |
|
- |
|
| Mortimer Ian |
PRESIDENT & CEO |
• • – |
2025-01-23 |
4 |
OE |
$17.76 |
$288,014 |
D/D |
16,217 |
47,519 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2024-12-18 |
4 |
S |
$41.19 |
$770,912 |
D/D |
(18,709) |
0 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2024-12-18 |
4 |
D |
$41.28 |
$273,480 |
D/D |
(6,625) |
11,510 |
|
- |
|
| Aulin Sherry |
Chief Financial Officer |
• – – |
2024-12-18 |
4 |
OE |
$9.44 |
$273,393 |
D/D |
25,334 |
16,000 |
|
- |
|
| Patou Gary |
|
– • – |
2024-11-22 |
4 |
S |
$41.05 |
$200,947 |
D/D |
(4,891) |
23,573 |
|
- |
|
| Patou Gary |
|
– • – |
2024-11-22 |
4 |
D |
$39.80 |
$67,461 |
D/D |
(1,695) |
25,613 |
|
- |
|
| Patou Gary |
|
– • – |
2024-11-22 |
4 |
OE |
$7.38 |
$67,429 |
D/D |
6,586 |
26,659 |
|
- |
|
| Garofalo Elizabeth A. |
|
– • – |
2024-03-08 |
4 |
S |
$45.69 |
$95,583 |
D/D |
(2,092) |
0 |
|
- |
|
| Garofalo Elizabeth A. |
|
– • – |
2024-03-08 |
4 |
D |
$46.16 |
$64,993 |
D/D |
(1,408) |
2,092 |
|
- |
|
| Garofalo Elizabeth A. |
|
– • – |
2024-03-08 |
4 |
OE |
$18.56 |
$64,960 |
D/D |
3,500 |
3,500 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2024-03-07 |
4 |
S |
$46.15 |
$330,290 |
D/D |
(7,137) |
8,398 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2024-03-07 |
4 |
D |
$45.96 |
$69,124 |
D/D |
(1,504) |
15,535 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2024-03-07 |
4 |
OE |
$9.85 |
$85,114 |
D/D |
8,641 |
16,824 |
|
- |
|
| Gannon Steven |
|
– • – |
2024-03-07 |
4 |
S |
$46.20 |
$601,615 |
D/D |
(13,000) |
2,000 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2023-12-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,398) |
8,398 |
|
- |
|
| Azab Mohammad |
|
– • – |
2023-12-19 |
4 |
OE |
$9.85 |
$42,552 |
D/D |
4,320 |
74,225 |
|
- |
|
| Patou Gary |
|
– • – |
2023-12-14 |
4/A |
S |
$41.05 |
$311,898 |
I/I |
(7,598) |
4,902 |
|
- |
|
| Patou Gary |
|
– • – |
2023-12-13 |
4 |
S |
$41.05 |
$311,898 |
I/I |
(7,598) |
4,902 |
|
- |
|
225 Records found
|
|
Page 1 of 9 |
|
|
